The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Kyle Alexander Mikson - Cantor Fitzgerald & Co., Research Division - Analyst
: I just wanted to confirm on the Lucid tests processed during the quarter. So 78 EsoGuard tests versus -- is that the number of tests that were
performed and then submitted for reimbursement or just simply performed? And then also, I know, Dennis, you talked about this a little bit, but
just I was wondering if you could provide a bit more detail on your expectation for the rate of claims denials for the rest of the year or even the
pacing of the cash collections as well because just -- I know it's a little bit uncertain, but I was wondering how we should be thinking about that?
Question: Kyle Alexander Mikson - Cantor Fitzgerald & Co., Research Division - Analyst
: All right. Makes sense. And sticking with Lucid and EsoGuard, I wanted to kind of -- I was wondering if you can kind of quantify the commercial
team. I was just wondering if you can provide any numbers around -- and I did hear a few of these, like, 2 clinical specialists, I think, I heard, but any
numbers around sales reps or sales managers, too?
Question: Kyle Alexander Mikson - Cantor Fitzgerald & Co., Research Division - Analyst
: Okay. That was helpful. I guess I'll ask one more, and I'll let others hop in. On Europe, I guess, could you just walk through the kind of the commercial
and the distribution strategy in Europe, assuming you receive CE Mark approval for EsoCheck and you're cleared for the EsoGuard assay as well?
And then similarly, what kind of issues would arise, I guess, or headwinds would be presented if you don't get the CE Mark approval by May 26, by
the time that the new regime begins?
|
